Phase 4
N=263
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT02061683 ↗Enrolled (actual)
263
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcome: Primary: Intraocular Pressure (IOP) in the Study Eye — 16.5; 16.7; 15.7; 16.1 Millimeters of Mercury (mmHg)
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Bimatoprost 0.03% (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Jun 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intraocular Pressure (IOP) in the Study Eye |
16.5; 16.7; 15.7; 16.1; 17.2 | — |
| SECONDARY Percentage of Patients With an Adverse Event of Conjunctival Hyperemia |
76.0 | — |
Summary
This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of open-angle glaucoma or ocular hypertension
- No use of Lumigan® in the past 3 months
Exclusion Criteria
- Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months
Data sourced from ClinicalTrials.gov (NCT02061683). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.